

Ref : ZLL/Compliance/LODR

Date: 12.05.2022

BSE Limited, Compliance Department, P. J. Towers, Dalal Street, MUMBAI – 400 001 Company Code – 541400

Dear Sirs,

Sub: Press Release for grant of Marketing Authorization for Sildenafil Citrate 50 mg Orally dissolving film in Spain, Europe.

Please find enclosed herewith our Press Release relating to grant of Marketing Authorization for Sildenafil Citrate 50 mg Orally dissolving film in Spain, Europe to Wholly-owned European Subsidiary of the company.

This is for your information and record.

Thanking you,

Yours faithfully, For ZIM LABORATORIES LIMITED

(Piyush Nikhade) Company Secretary and Compliance Officer

Encl: As above.

ZIM LABORATORIES LIMITED

PRESS RELEASE

ZIM Laboratories Limited

Announces Grant of Marketing Authorization for Sildenafil 50 mg Orally Dissolving Film in Spain, Europe.

Nagpur, India May 12, 2022:

ZIM Laboratories Limited, a pharmaceutical company which manufactures differentiated generic products based on R&D and innovative process technologies is pleased to announce today that AEPMS - The Spanish Agency for Medicine and Healthcare Products has granted Marketing Authorisation for it's innovative product "Sildenafil 50 mg" ODS in Spain to it's wholly owned European Subsidiary – SIA ZIM Laboratories Limited.

ZIM Labs is a pioneer in developing Oral Thin Films ("OTF") an innovative and novel drug delivery dosage form. The above product is developed using patented Thinoral® technology, which yields instantly wettable, rapidly dissolving, and stable orally dissolving films.

The conventional dosage form such as tablet and capsule are difficult to administer, may poses choking hazards and unfriendly to patient convenience. Against the odds of drug intake, oral thin film dissolves instantly after placing on the tongue and results in faster action. Unique features of OTFs and it's flexibility offers unparalleled convenience in drug handling and administration.

According to various global research institutions, the market of sildenafil is expected to gain healthy growth in the forecast period of 2021 to 2028. Rising adoption of sedentary lifestyle and increasing incidence of lifestyle diseases are further anticipated to fuel the growth.

Dr. Anwar Daud, Chairman & Managing Director of ZIM Laboratories, gladly commented on the authorization, "The marketing approval for Sildenafil Oral Thin Films can be viewed as a further assurance that ZIM laboratories with it's R&D capabilities and high quality manufacturing standards can become a promising partner for the overseas clients who look for the cost effective innovative drug delivery solutions to meet global market challenges and cater the needs of patients and medical professionals".

About ZIM Laboratories Limited

ZIM Laboratories Limited is a research-driven pharmaceutical company which develops, manufactures and supplies differentiated generic products in the oral solid dosage forms, both as pre-formulation intermediates and finished formulations for certain key therapeutic segments. ZIM has in-house R&D capabilities to offer a range of non-infringing drug delivery solutions based on process technologies that bring patient compliance thereby reducing the cost of treatment. ZIM is listed on BSE Limited.

References:

- 1.https://www.industryarc.com/Research/Sildenafil-Citrate-Market-Research-501922
- 2.https://www.grandviewresearch.com/industry-analysis/erectile-dysfunction-drugs-market